Related Experiment Video
Updated: Oct 16, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment
Shuai Guo1, Xue Bai1, Sai Shi2
1School of Life Science, Hebei University, Baoding 071002, China 2 Key Laboratory of Molecular Biophysics, Institute of Biophysics, School of Sciences, Hebei University of Technology, Tianjin 300401, China.
Abstract:
Lung cancer has the highest rate of incidence and mortality among all cancers. Most chemotherapeutic drugs used to treat lung cancer cause serious side effects and are susceptible to drug resistance. Therefore, exploring novel therapeutic targets for lung cancer is important. In this study, we evaluated the potential of TMEM16A as a drug target for lung cancer. Homoharringtonine (HHT) was identified as a novel natural product inhibitor of TMEM16A. Patch-clamp experiments showed that HHT inhibited TMEM16A activity in a concentration-dependent manner. HHT significantly inhibited the proliferation and migration of lung cancer cells with high TMEM16A expression but did not affect the growth of normal lung cells in the absence of TMEM16A expression. In vivo experiments showed that HHT inhibited the growth of lung tumors in mice and did not reduce their body weight. Finally, the molecular mechanism through which HHT inhibits lung cancer was explored by western blotting. The findings showed that HHT has the potential to regulate TMEM16A activity both in vitro and in vivo and could be a new lead compound for the development of anti-lung-cancer drugs.
Insights
Homoharringtonine (HHT) effectively inhibits TMEM16A, a promising target for lung cancer therapy. This natural compound suppressed lung cancer cell proliferation and tumor growth without harming normal cells, offering a potential new drug lead.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Lung cancer exhibits high incidence and mortality rates globally.
- Current chemotherapies for lung cancer present significant side effects and drug resistance issues.
- Identifying novel therapeutic targets is crucial for effective lung cancer treatment.
Purpose of the Study:
- To investigate the potential of TMEM16A as a therapeutic drug target for lung cancer.
- To evaluate Homoharringtonine (HHT) as a novel inhibitor of TMEM16A.
- To explore the efficacy and mechanism of HHT in preclinical lung cancer models.
Main Methods:
- Patch-clamp electrophysiology to assess TMEM16A channel activity.
- In vitro cell proliferation and migration assays using lung cancer cell lines.
- In vivo studies using mouse models to evaluate tumor growth inhibition.
- Western blotting to elucidate molecular mechanisms of action.
Main Results:
- Homoharringtonine (HHT) demonstrated concentration-dependent inhibition of TMEM16A.
- HHT significantly inhibited proliferation and migration of TMEM16A-expressing lung cancer cells.
- HHT treatment did not affect normal lung cell growth and reduced tumor growth in vivo without causing weight loss.
- Western blotting revealed HHT's role in regulating TMEM16A activity.
Conclusions:
- TMEM16A is a viable drug target for lung cancer therapy.
- Homoharringtonine (HHT) is a potent natural inhibitor of TMEM16A with anti-lung cancer properties.
- HHT shows potential as a novel lead compound for developing new anti-lung cancer drugs.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle